Ritlecitinib

Independent reference data for Ritlecitinib (CAS 1792180-81-4), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.Ritlecitinib is an orally available small molecule inhibitor of Janus kinase 3 (JAK3) that is used to treat severe alopecia areata. Ritlecitinib is associated with a low rate of transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.

Synonyms and trade names

ritlecitinib; 1792180-81-4; PF-06651600; 2OYE00PC25; 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one; 2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-; PF06651600; PF 06651600; 2-PROPEN-1-ONE, 1-((2S,5R)-2-METHYL-5-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-1-PIPERIDINYL)-; 1-((2S,5R)-2-methyl-5-((7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one; 1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)piperidin-1-yl)prop-2-en-1-one; 1-[(2S,5R)-2-methyl-5-{7H-pyrrolo[2,3-d]pyrimidin-4-ylamino}piperidin-1-yl]prop-2-en-1-one; 1-{(2S,5R)-2-Methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one; RefChem:179511; JAK3 Inhibitor PF-06651600; 815-269-7

GHS hazard classification

Reported hazard statements	H361 (100%)

H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

What the public record says

Ritlecitinib · CAS 1792180-81-4 · C15H19N5O. UNII 2OYE00PC25.

Source: PubChem / Wikidata; the batch COA governs where values differ.